Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Poll|May 11, 2015
Check Your Bipolar Acumen
Author(s)Psychiatric Times Editors
Lithium, neuroimaging, and medical comorbidities in bipolar disorder: here's a 3 question mini-quiz from the very recent literature.
Advertisement
Three questions from the very recent literature about bipolar disorder follow.
1. Which of the following statements about lithium therapy in patients with bipolar disorder is true?
Advertisement
Related to this article
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
5